77 results
Page 4 of 4
F-1
izd6dz890gmy66yw0yw
31 Jan 20
Registration statement (foreign)
12:00am
6-K
EX-99.1
7d1jxy1febkude8g4l
11 Dec 19
Annual and Special General Meeting of Shareholders
4:38pm
424B5
po8inj ahmv6
5 Dec 19
Prospectus supplement for primary offering
5:29pm
6-K
EX-99.2
ap5zi1axu6 iknlor
7 Nov 19
Therapix Biosciences and Destiny Biosciences Global Corp. Mutually Decide to Discontinue Negotiations on Planned Merger
5:22pm
F-3/A
kti0z1
29 Aug 19
Shelf registration (foreign) (amended)
4:49pm
F-3
p5yjt9gz43oxdt8fts
22 Aug 19
Shelf registration (foreign)
5:25pm
6-K
EX-99.1
9smifqmra0up3kk1fi
31 Jul 19
Therapix Biosciences Announces Canadian Product License Issuance for TheraPEA (CannAmide™), a Non-Opiate Based Pain Management Supplement
4:03pm
424B5
zg3cte0ydvj
1 Apr 19
Prospectus supplement for primary offering
6:57am
6-K
EX-99.1
cdfw4i 0knebnswyspwv
19 Mar 19
Therapix Biosciences Appoints Ambassador Ron Prosor as Executive Advisor
8:04am
6-K
EX-99.1
l28 8mr682h
17 Jan 19
Annual General Meeting of Shareholders
4:05pm
6-K
EX-99.1
brjwxrc49yc5c912hk7n
28 Nov 18
Management’s Discussion and Analysis of Financial Condition and Results of Operations
6:27am
424B2
obfr7r0096ewr0wud
9 Aug 18
Prospectus for primary offering
11:19am
F-3/A
pblu6
17 Jul 18
Shelf registration (foreign) (amended)
1:29pm
F-3
sfg6 i6k23z18uolxi
20 Jun 18
Shelf registration (foreign)
2:38pm
6-K
x3kc3p4wj74p
17 May 18
Report of Foreign Private Issuer
7:44am
20-F
04q8rkd2 pri83sfvcl0
1 May 17
Annual report (foreign)
12:00am